New hope for leukemia patients: targeted therapy aims to eliminate hidden cancer cells

This study tests whether a targeted drug called gemtuzumab ozogamicin can clear tiny amounts of leukemia that remain after initial treatment in adults with acute myeloid leukemia (AML). The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a chemotherapy payload directly to them. About 36 participants will receive the drug in divided doses, and researchers will check if it can eliminate these leftover cancer cells without causing severe side effects.